Similarly, the multi-institutional NEXIS study is recruiting non-RPS patients with high or intermediate-grade sarcoma for a study of durvalumab (PD-L1 inhibitor) and tremelimumab (anti-CTLA4) during neoadjuvant RT and in the adjuvant setting [96]. This evidence concerns the gene CD274 and sarcoma.